Danyang Li

Danyang Li

Auto-generated profile, based on publicly available information

Danyang Li

Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing 100081, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DLDanyang Li
Danyang Li
ZQZhenzhen Quan
Zhenzhen Quan
JNJunjun Ni
Junjun Ni
HLHui Li
Hui Li
HQHong Qing
Hong Qing
Zinc finger protein 335 (ZNF335) plays a crucial role in the methylation and, consequently, regulates the expression of a specific set of genes. Variants of the ZNF335 gene have been identified as risk factors for microcephaly in a variety of populations worldwide. Meanwhile, ZNF335 has also been identified as an essential regulator of T-cell development. However, an in-depth understanding of the role of ZNF335 in brain development and T cell maturation is still lacking. In this review, we summarize current knowledge of the molecular mechanisms underlying the involvement of ZNF335 in neuronal and T cell development across a wide range of pre-clinical, post-mortem, ex vivo, in vivo, and clinical studies. We also review the current limitations regarding the study of the pathophysiological functions of ZNF335. Finally, we hypothesize a potential role for ZNF335 in brain disorders and discuss the rationale of targeting ZNF335 as a therapeutic strategy for preventing brain disorders.

6 November 2026 in BioTech
Verified
Journal Article
Open access
PDF file
YLYuanfei Liu
Yuanfei Liu
DLDanyang Li
Danyang Li
XLXinyang Li
Xinyang Li
Minglian WangMinglian Wang
Minglian Wang
Small extracellular vesicles (sEVs), commonly referred to as exosomes, are nanoscale vesicles that mediate intercellular communication and represent promising biotechnological platforms for disease diagnosis, therapeutic intervention, and drug delivery. sEVs derived from plants, mesenchymal stem cells, tumor cells, and immune cells display pronounced source-dependent heterogeneity shaped by parental cell lineage, differentiation status, and the local microenvironment. Such heterogeneity influences not only their biological properties, including physicochemical characteristics, molecular cargo profiles, and immunomodulatory functions, but also their manufacturing characteristics, in vivo tropism, and translational potential as biotherapeutics. Nevertheless, a comprehensive evaluation framework from a medical biotechnology perspective remains insufficiently established. In this review, the core biological features of multi-source sEVs are first outlined to establish a foundation for subsequent analysis. We then examine their biomedical applications and discuss biotechnological bottlenecks, including isolation and purification workflows, quality-control metrics, batch-to-batch variability, scalable biomanufacturing, and biosafety assessment. Particular attention is also given to the incompletely characterized regulatory networks of immune-cell-derived sEVs. Furthermore, we discuss how multi-omics profiling, standardized production protocols, and precision-engineering strategies may facilitate the functional optimization of source-specific sEVs. Collectively, this review provides an integrated medical biotechnology framework for evaluating multi-source sEVs and highlights practical considerations for accelerating the bench-to-bedside translation of sEV-based biotherapeutics.